Cancer biomarkers

From Wikipedia, the free encyclopedia
Jump to: navigation, search
text
Questions that can be answered by biomarkers

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.[1]

While numerous challenges exist in translating biomarker research into the clinical space; a number of gene and protein based biomarkers have already been used at some point in patient care; including, AFP (Liver Cancer), BCR-ABL (Chronic Myeloid Leukemia), BRCA1 / BRCA2 (Breast/Ovarian Cancer), BRAF V600E (Melanoma/Colorectal Cancer), CA-125 (Ovarian Cancer), CA19.9 (Pancreatic Cancer), CEA (Colorectal Cancer), EGFR (Non-small-cell lung carcinoma), HER-2 (Breast Cancer), KIT (Gastrointestinal stromal tumor), PSA (Prostate Specific Antigen) (Prostate Cancer), S100 (Melanoma), and many others.[2][3][4][5][6][7][8][9][10][11]

Definitions of cancer biomarkers[edit]

Organizations and publications vary in their definition of biomarker. In many areas of medicine, biomarkers are limited to proteins identifiable or measurable in the blood or urine. However, the term is often used to cover any molecular, biochemical, physiological, or anatomical property that can be quantified or measured.

The National Cancer Institute (NCI), in particular, defines biomarker as a: “A biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule." [12]

In cancer research and medicine, biomarkers are used in three primary ways:[13]

  1. To help diagnose conditions, as in the case of identifying early stage cancers (Diagnostic)
  2. To forecast how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment (Prognostic)
  3. To predict how well a patient will respond to treatment (Predictive)

Role of biomarkers in cancer research and medicine[edit]

Uses of Biomarkers in cancer medicine[edit]

Risk assessment[edit]

Cancer biomarkers, particular those associated with genetic mutations or epigenetic alterations, often offer a quantitative way to determine when individuals are predisposed to particular types of cancers. Notable examples of potentially predictive cancer biomarkers include mutations on genes KRAS, p53, EGFR, erbB2 for colorectal, esophageal, liver, and pancreatic cancer; mutations of genes BRCA1 and BRCA2 for breast and ovarian cancer; abnormal methylation of tumor suppressor genes p16, CDKN2B, and p14ARF for brain cancer; hypermethylation of MYOD1, CDH1, and CDH13 for cervical cancer; and hypermethylation of p16, p14, and RB1, for oral cancer.[14]

Diagnosis[edit]

Cancer biomarkers can also be useful in establishing a specific diagnosis. This is particularly the case when there is a need to determine whether tumors are of primary or metastatic origin. To make this distinction, researchers can screen the chromosomal alterations found on cells located in the primary tumor site against those found in the secondary site. If the alterations match, the secondary tumor can be identified as metastatic; whereas if the alterations differ, the secondary tumor can be identified as a distinct primary tumor.[15]

Prognosis and treatment predictions[edit]

Another use of biomarkers in cancer medicine is for disease prognosis, which take place after an individual has been diagnosed with cancer. Here biomarkers can be useful in determining the aggressiveness of an identified cancer as well as its likelihood of responding to a given treatment. In part, this is because tumors exhibiting particular biomarkers may be responsive to treatments tied to that biomarker's expression or presence. Examples of such prognostic biomarkers include elevated levels of metallopeptidase inhibitor 1 (TIMP1), a marker associated with more aggressive forms of multiple myeloma,[16] elevated estrogen receptor (ER) and/or progesterone receptor (PR) expression, markers associated with better overall survival in patients with breast cancer;[17][18] HER2/neu gene amplification, a marker indicating a breast cancer will likely respond to trastuzumab treatment;[19][20] a mutation in exon 11 of the proto-oncogene c-KIT, a marker indicating a gastrointestinal stromal tumor (GIST) will likely respond to imatinib treatment;[21][22] and mutations in the tyrosine kinase domain of EGFR1, a marker indicating a patient's non-small-cell lung carcinoma (NSCLC) will likely respond to gefitinib or erlotinib treatment.[23][24]

Pharmacodynamics and pharmacokinetics[edit]

Cancer biomarkers can also be used to determine the most effective treatment regime for a particular person's cancer.[25] Because of differences in each person's genetic makeup, some people metabolize or change the chemical structure of drugs differently. In some cases, decreased metabolism of certain drugs can create dangerous conditions in which high levels of the drug accumulate in the body. As such, drug dosing decisions in particular cancer treatments can benefit from screening for such biomarkers. An example is the gene encoding the enzyme thiopurine methyl-transferase (TPMPT).[26] Individuals with mutations in the TPMT gene are unable to metabolize large amounts of the leukemia drug, mercaptopurine, which potentially causes a fatal drop in white blood count for such patients. Patients with TPMT mutations are thus recommended to be given a lower dose of mercaptopurine for safety considerations.[27]

Monitoring treatment response[edit]

Cancer biomarkers have also shown utility in monitoring how well a treatment is working over time. Much research is going into this particular area, since successful biomarkers have the potential of providing significant cost reduction in patient care, as the current image-based tests such as CT and MRI for monitoring tumor status are highly costly.[28]

One notable biomarker garnering significant attention is the protein biomarker S100-beta in monitoring the response of malignant melanoma. In such melanomas, melanocytes, the cells that make pigment in our skin, produce the protein S100-beta in high concentrations dependent on the number of cancer cells. Response to treatment is thus associated with reduced levels of S100-beta in the blood of such individuals.[29][30]

Similarly, additional laboratory research has shown that tumor cells undergoing apoptosis can release cellular components such as cytochrome c, nucleosomes, cleaved cytokeratin-18, and E-cadherin. Studies have found that these macromolecules and others can be found in circulation during cancer therapy, providing a potential source of clinical metrics for monitoring treatment.[28]

Recurrence[edit]

Cancer biomarkers can also offer value in predicting or monitoring cancer recurrence. The Oncotype DX® breast cancer assay is one such test used to predict the likelihood of breast cancer recurrence. Thist test is intended for women with early-stage (Stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy. Oncotype DX looks at a panel of 21 genes in cells taken during tumor biopsy. The results of the test are given in the form of a recurrence score that indicates likelihood of recurrence at 10 years.[31][32]

Uses of biomarkers in cancer research[edit]

Developing drug targets[edit]

In addition to their use in cancer medicine, biomarkers are often used throughout the cancer drug discovery process. For instance, in the 1960s, researchers discovered the majority of patients with chronic myelogenous leukemia possessed a particular genetic abnormality on chromosomes 9 and 22 dubbed the Philadelphia chromosome. When these two chromosomes combine they create a cancer-causing gene known as BCR-ABL. In such patients, this gene acts as the principle initial point in all of the physiological manifestations of the leukemia. For many years, the BCR-ABL was simply used as a biomarker to stratify a certain subtype of leukemia. However, drug developers were eventually able to develop imatinib, a powerful drug that effecively inhibited this protein and significantly decreased production of cells containing the Philadelphia chromosome.[33][34]

Surrogate endpoints[edit]

Another promising area of biomarker application is in the area of surrogate endpoints. In this application, biomarkers act as stand-ins for the effects of a drug on cancer progression and survival. Ideally, the used of validated biomarkers would prevent patients from having to undergo tumor biopsies and lengthy clinical trials to determine if a new drug worked. In the current standard of care, the metric for determining a drug's effectiveness is to check if it has decreased cancer progression in humans and ultimately whether it prolongs survival. However, successful biomarker surrogates could save substantial time, effort, and money if failing drugs could be eliminated from the development pipeline before being brought to clinical trials.

Some ideal characteristics of surrogate endpoint biomarkers include:[35][36]

  • Biomarker should be involved in process that causes the cancer
  • Changes in biomarker should correlate with changes in the disease
  • Levels of biomarkers should be high enough that they can be measured easily and reliably
  • Levels or presence of biomarker should readily distinguish between normal, cancerous, and precancerous tissue
  • Effective treatment of the cancer should change the level of the biomarker
  • Level of the biomarker should not change spontaneously or in response to other factors not related to the successful treatment of the cancer

Two areas in particular that are receiving attention as surrogate markers include circulating tumor cells (CTCs)[37][38] and circulating miRNAs.[39][40] Both these markers are associated with the number of tumor cells present in the blood, and as such, are hoped to provide a surrogate for tumor progression and metastasis. However, significant barriers to their adoption include the difficulty of enriching, identifying, and measuring CTC and miRNA levels in in blood. New technologies and research are likely necessary for their translation into clinical care.[41][42]

Types of cancer biomarkers[edit]

Molecular cancer biomarkers[edit]

Tumor Type Biomarker
Breast ER/PR (estrogen receptor/progesteron receptor)[43][44]
HER-2/neu [43][44]
Colorectal EGFR [43][44]
KRAS [43][45]
UGT1A1 [43][45]
Gastric HER-2/neu [43]
GIST c-KIT [43][46]
Leukemia/Lymphoma CD20 Antigen [43][47]
CD30 [43][48]
FIP1L1-PDGRFalpha [43][49]
PDGFR [43][50]
Philadelphia Chromosome (BCR/ABL) [43][51][52]
PML/RAR alpha [43][53]
TPMT [43][54]
UGT1A1 [43][55]
Lung ALK [43][56][57]
EGFR [43][44]
KRAS [43][44]
Melanoma BRAF [43][57]

Other Examples of Biomarkers:

References[edit]

  1. ^ Mishra, Alok; Verma, Mukesh (2010). "Cancer Biomarkers: Are We Ready for the Prime Time?". Cancers 2 (1): 190–208. doi:10.3390/cancers2010190. 
  2. ^ Rhea, Jeanne; Ross J. Molinaro (March 2011). "Cancer Biomarkers: Surviving the journey from bench to bedside". Medical Laboratory Observer. Retrieved 26 April 2013. 
  3. ^ Behne, Tara; Copur, M. Sitki (1 January 2012). "Biomarkers for Hepatocellular Carcinoma". International Journal of Hepatology 2012: 1–7. doi:10.1155/2012/859076. 
  4. ^ Musolino, A; Bella, MA; Bortesi, B; Michiara, M; Naldi, N; Zanelli, P; Capelletti, M; Pezzuolo, D; Camisa, R; Savi, M; Neri, TM; Ardizzoni, A (June 2007). "BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.". Breast (Edinburgh, Scotland) 16 (3): 280–92. doi:10.1016/j.breast.2006.12.003. PMID 17257844. 
  5. ^ Dienstmann, R; Tabernero, J (March 2011). "BRAF as a target for cancer therapy.". Anti-cancer agents in medicinal chemistry 11 (3): 285–95. doi:10.2174/187152011795347469. PMID 21426297. 
  6. ^ Lamparella, N; Barochia, A; Almokadem, S (2013). "Impact of genetic markers on treatment of non-small cell lung cancer.". Advances in experimental medicine and biology 779: 145–64. doi:10.1007/978-1-4614-6176-0_6. PMID 23288638. 
  7. ^ Orphanos, G; Kountourakis, P (2012). "Targeting the HER2 receptor in metastatic breast cancer.". Hematology/oncology and stem cell therapy 5 (3): 127–37. doi:10.5144/1658-3876.2012.127. PMID 23095788. 
  8. ^ DePrimo, S. E.; Huang, X.; Blackstein, M. E.; Garrett, C. R.; Harmon, C. S.; Schoffski, P.; Shah, M. H.; Verweij, J.; Baum, C. M.; Demetri, G. D. (8 September 2009). "Circulating Levels of Soluble KIT Serve as a Biomarker for Clinical Outcome in Gastrointestinal Stromal Tumor Patients Receiving Sunitinib following Imatinib Failure". Clinical Cancer Research 15 (18): 5869–5877. doi:10.1158/1078-0432.CCR-08-2480. 
  9. ^ Bantis, A; Grammaticos, P (Sep–Dec 2012). "Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?". Hellenic journal of nuclear medicine 15 (3): 241–6. PMID 23227460. 
  10. ^ Kruijff, S; Hoekstra, HJ (April 2012). "The current status of S-100B as a biomarker in melanoma.". European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 38 (4): 281–5. doi:10.1016/j.ejso.2011.12.005. PMID 22240030. 
  11. ^ Ludwig, JA; Weinstein, JN (November 2005). "Biomarkers in cancer staging, prognosis and treatment selection.". Nature Reviews Cancer 5 (11): 845–56. doi:10.1038/nrc1739. PMID 16239904. 
  12. ^ "biomarker". NCI Dictionary of Cancer Terms. National Cancer Institute. 
  13. ^ "Biomarkers in Cancer: An Introductory Guide for Advocates". Research Advocay Network. 2010. Retrieved 26 April 2013. 
  14. ^ Verma, M; Manne, U (October 2006). "Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations.". Critical reviews in oncology/hematology 60 (1): 9–18. doi:10.1016/j.critrevonc.2006.04.002. PMID 16829121. 
  15. ^ Leong, PP; Rezai, B; Koch, WM; Reed, A; Eisele, D; Lee, DJ; Sidransky, D; Jen, J; Westra, WH (Jul 1, 1998). "Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.". Journal of the National Cancer Institute 90 (13): 972–7. doi:10.1093/jnci/90.13.972. PMID 9665144. 
  16. ^ Terpos E, Dimopoulos MA, Shrivastava V, et al. (March 2010). "High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents". Leuk. Res. 34 (3): 399–402. doi:10.1016/j.leukres.2009.08.035. PMID 19781774. 
  17. ^ Kuukasjärvi, T; Kononen, J; Helin, H; Holli, K; Isola, J (September 1996). "Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 14 (9): 2584–9. PMID 8823339. 
  18. ^ Harris, L; Fritsche, H; Mennel, R; Norton, L; Ravdin, P; Taube, S; Somerfield, MR; Hayes, DF; Bast RC, Jr; American Society of Clinical, Oncology (Nov 20, 2007). "American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25 (33): 5287–312. doi:10.1200/JCO.2007.14.2364. PMID 17954709. 
  19. ^ Kröger, N; Milde-Langosch, K; Riethdorf, S; Schmoor, C; Schumacher, M; Zander, AR; Löning, T (Jan 1, 2006). "Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.". Clinical cancer research : an official journal of the American Association for Cancer Research 12 (1): 159–68. doi:10.1158/1078-0432.CCR-05-1340. PMID 16397038. 
  20. ^ Vrbic, S; Pejcic, I; Filipovic, S; Kocic, B; Vrbic, M (Jan–Mar 2013). "Current and future anti-HER2 therapy in breast cancer.". Journal of B.U.ON. : official journal of the Balkan Union of Oncology 18 (1): 4–16. PMID 23613383. 
  21. ^ Yoo, C; Ryu, MH; Ryoo, BY; Beck, MY; Kang, YK (Apr 17, 2013). "Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.". Investigational new drugs 31 (5): 1367–74. doi:10.1007/s10637-013-9961-8. PMID 23591629. 
  22. ^ Demetri, GD; van Oosterom, AT; Garrett, CR; Blackstein, ME; Shah, MH; Verweij, J; McArthur, G; Judson, IR; Heinrich, MC; Morgan, JA; Desai, J; Fletcher, CD; George, S; Bello, CL; Huang, X; Baum, CM; Casali, PG (Oct 14, 2006). "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.". Lancet 368 (9544): 1329–38. doi:10.1016/S0140-6736(06)69446-4. PMID 17046465. 
  23. ^ Herbst, RS; Prager, D; Hermann, R; Fehrenbacher, L; Johnson, BE; Sandler, A; Kris, MG; Tran, HT; Klein, P; Li, X; Ramies, D; Johnson, DH; Miller, VA; TRIBUTE Investigator, Group (Sep 1, 2005). "TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.". Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23 (25): 5892–9. doi:10.1200/JCO.2005.02.840. PMID 16043829. 
  24. ^ Lynch, TJ; Bell, DW; Sordella, R; Gurubhagavatula, S; Okimoto, RA; Brannigan, BW; Harris, PL; Haserlat, SM; Supko, JG; Haluska, FG; Louis, DN; Christiani, DC; Settleman, J; Haber, DA (May 20, 2004). "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.". The New England Journal of Medicine 350 (21): 2129–39. doi:10.1056/NEJMoa040938. PMID 15118073. 
  25. ^ Sawyers CL (April 2008). "The cancer biomarker problem". Nature 452 (7187): 548–52. doi:10.1038/nature06913. PMID 18385728. 
  26. ^ Karas-Kuzelicki, N; Mlinaric-Rascan, I (August 2009). "Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.". Pharmacogenomics 10 (8): 1309–22. doi:10.2217/pgs.09.78. PMID 19663675. 
  27. ^ Relling MV, Hancock ML, Rivera GK, et al. (December 1999). "Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus". J. Natl. Cancer Inst. 91 (23): 2001–8. doi:10.1093/jnci/91.23.2001. PMID 10580024. 
  28. ^ a b Schneider, John; Manpreet K Sidhu; Cynthia Doucet; Noemi Kiss; Robert L Ohsfeldt; Donald Chalfin (2012). "Economics of Cancer Biomarkers". Personalized Medicine 9 (8): 829–837. doi:10.2217/pme.12.87. 
  29. ^ Henze, G; Dummer, R; Joller-Jemelka, HI; Böni, R; Burg, G (1997). "Serum S100--a marker for disease monitoring in metastatic melanoma.". Dermatology (Basel, Switzerland) 194 (3): 208–12. doi:10.1159/000246103. PMID 9187834. 
  30. ^ Harpio, R; Einarsson, R (July 2004). "S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.". Clinical biochemistry 37 (7): 512–8. doi:10.1016/j.clinbiochem.2004.05.012. PMID 15234232. 
  31. ^ Lamond, NW; Skedgel, C; Younis, T (April 2013). "Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer?". Expert review of pharmacoeconomics & outcomes research 13 (2): 243–50. doi:10.1586/erp.13.4. PMID 23570435. 
  32. ^ Biroschak, JR; Schwartz, GF; Palazzo, JP; Toll, AD; Brill, KL; Jaslow, RJ; Lee, SY (May 2013). "Impact of Oncotype DX on Treatment Decisions in ER-Positive, Node-Negative Breast Cancer with Histologic Correlation.". The breast journal 19 (3): 269–75. doi:10.1111/tbj.12099. PMID 23614365. 
  33. ^ Moen, MD; McKeage, K; Plosker, GL; Siddiqui, MA (2007). "Imatinib: a review of its use in chronic myeloid leukaemia.". Drugs 67 (2): 299–320. doi:10.2165/00003495-200767020-00010. PMID 17284091. 
  34. ^ Lemonick, Michael; Alice Park (May 28, 2001). "New Hope for Cancer". Time Magazine. Retrieved 26 April 2013. 
  35. ^ Price, C; McDonnell, D (February 1991). "Effects of niobium filtration and constant potential on the sensitometric responses of dental radiographic films.". Dento maxillo facial radiology 20 (1): 11–6. PMID 1884846. 
  36. ^ Cohen, Victor; Fadlo Khuri (2003). "Progress in Lung Cancer Chemoprevention". Cancer Control 10 (4): 315–324. Retrieved 26 April 2013. 
  37. ^ Lu, CY; Tsai, HL; Uen, YH; Hu, HM; Chen, CW; Cheng, TL; Lin, SR; Wang, JY (Mar 5, 2013). "Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer.". British journal of cancer 108 (4): 791–7. doi:10.1038/bjc.2012.595. PMID 23422758. 
  38. ^ Balic, M; Williams, A; Lin, H; Datar, R; Cote, RJ (2013). "Circulating tumor cells: from bench to bedside.". Annual review of medicine 64: 31–44. doi:10.1146/annurev-med-050311-163404. PMID 23092385. 
  39. ^ Madhavan, D; Zucknick, M; Wallwiener, M; Cuk, K; Modugno, C; Scharpff, M; Schott, S; Heil, J; Turchinovich, A; Yang, R; Benner, A; Riethdorf, S; Trumpp, A; Sohn, C; Pantel, K; Schneeweiss, A; Burwinkel, B (Nov 1, 2012). "Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.". Clinical cancer research : an official journal of the American Association for Cancer Research 18 (21): 5972–82. doi:10.1158/1078-0432.CCR-12-1407. PMID 22952344. 
  40. ^ Redova, M; Sana, J; Slaby, O (March 2013). "Circulating miRNAs as new blood-based biomarkers for solid cancers.". Future oncology (London, England) 9 (3): 387–402. doi:10.2217/fon.12.192. PMID 23469974. 
  41. ^ Joosse, SA; Pantel, K (Jan 1, 2013). "Biologic challenges in the detection of circulating tumor cells.". Cancer Research 73 (1): 8–11. doi:10.1158/0008-5472.CAN-12-3422. PMID 23271724. 
  42. ^ Hou, HW; Warkiani, ME; Khoo, BL; Li, ZR; Soo, RA; Tan, DS; Lim, WT; Han, J; Bhagat, AA; Lim, CT (2013). "Isolation and retrieval of circulating tumor cells using centrifugal forces.". Scientific reports 3: 1259. doi:10.1038/srep01259. PMID 23405273. 
  43. ^ a b c d e f g h i j k l m n o p q r s "Table of Pharmacogenomic Biomarkers in Drug Labels". U.S Food and Drug Administration. 
  44. ^ a b c d e "Tumor Markers Fact Sheet" (PDF). American Cancer Society. 
  45. ^ a b Lenz, Heinz-Josef. EdBk.GI.Colo.04.pdf "Established Biomarkers in Colon Cancer" (PDF). American Society of Clinical Oncology’s 2009 Educational Book. 
  46. ^ Gonzalez RS, Carlson G, Page AJ, Cohen C (July 2011). "Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome". Am. J. Clin. Pathol. 136 (1): 74–80. doi:10.1309/AJCP9KHD7DCHWLMO. PMID 21685034. 
  47. ^ Tam CS, Otero-Palacios J, Abruzzo LV, et al. (April 2008). "Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients". Br. J. Haematol. 141 (1): 36–40. doi:10.1111/j.1365-2141.2008.07012.x. PMID 18324964. 
  48. ^ Zhang M, Yao Z, Patel H, et al. (May 2007). "Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1". Proc. Natl. Acad. Sci. U.S.A. 104 (20): 8444–8. doi:10.1073/pnas.0702496104. PMC 1895969. PMID 17488826. 
  49. ^ Yamada Y, Sanchez-Aguilera A, Brandt EB, et al. (September 2008). "FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome". Blood 112 (6): 2500–7. doi:10.1182/blood-2007-11-126268. PMID 18539901. 
  50. ^ Nimer SD (May 2008). "Myelodysplastic syndromes". Blood 111 (10): 4841–51. doi:10.1182/blood-2007-08-078139. PMID 18467609. 
  51. ^ Ottmann O, Dombret H, Martinelli G, et al. (October 2007). "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study". Blood 110 (7): 2309–15. doi:10.1182/blood-2007-02-073528. PMID 17496201. 
  52. ^ Boulos N, Mulder HL, Calabrese CR, et al. (March 2011). "Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia". Blood 117 (13): 3585–95. doi:10.1182/blood-2010-08-301267. PMC 3072880. PMID 21263154. 
  53. ^ O'Connell PA, Madureira PA, Berman JN, Liwski RS, Waisman DM (April 2011). "Regulation of S100A10 by the PML-RAR-α oncoprotein". Blood 117 (15): 4095–105. doi:10.1182/blood-2010-07-298851. PMID 21310922. 
  54. ^ Duffy MJ, Crown J (November 2008). "A personalized approach to cancer treatment: how biomarkers can help". Clin. Chem. 54 (11): 1770–9. doi:10.1373/clinchem.2008.110056. PMID 18801934. 
  55. ^ Ribrag V, Koscielny S, Casasnovas O, et al. (April 2009). "Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis". Blood 113 (14): 3307–13. doi:10.1182/blood-2008-03-148874. PMID 18768784. 
  56. ^ Li Y, Ye X, Liu J, Zha J, Pei L (January 2011). "Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors". Neoplasia 13 (1): 1–11. PMC 3022423. PMID 21245935. 
  57. ^ a b Pao W, Girard N (February 2011). "New driver mutations in non-small-cell lung cancer". Lancet Oncol. 12 (2): 175–80. doi:10.1016/S1470-2045(10)70087-5. PMID 21277552. 
  58. ^ Bartels CL, Tsongalis GJ (April 2009). "MicroRNAs: novel biomarkers for human cancer". Clin. Chem. 55 (4): 623–31. doi:10.1373/clinchem.2008.112805. PMID 19246618. 

External links[edit]